期刊文献+

替米沙坦与吲哒帕胺联合治疗高血压的临床疗效

The clinical effect of telmisartan combined with indapamide in treatment to hypertension
下载PDF
导出
摘要 目的评价替米沙坦与吲哒帕胺联用治疗轻、中度高血压的临床疗效与安全性。方法采用随机平行对照方法,将原发性轻、中度高血压患者74例分成3组。对照组(n=24)予以替米沙坦(40mg/d,每日1次);治疗组Ⅰ(n=25)在服用替米沙坦(20mg/d)基础上,加服吲哒帕胺(1.25nag,每日1次);治疗组Ⅱ(n=25)在服用替米沙坦(20mg/d)基础上,加服酒石酸美托洛尔(25mg,每日2次)。疗程均为8周。结果治疗8周后,治疗组Ⅰ和治疗组Ⅱ,总有效率分别为92.0%和83.3%,前者与对照组总有效率62.5%比较,P〈0.05;后者与对照组比较,P〉0.05。对照组、治疗组Ⅰ和治疗组Ⅱ不良反应发生例数分别为4、3、1例。结论低剂量替米沙坦与吲哒帕胺联用治疗轻、中度高血压较单用替米沙坦降压效果好。 Object To evaluate the antihypertensive efficacy and safety of telmisartan. Methods Seventy -four patients with mild to moderate essential hypertension were randomly divided into 3 groups : the test groupⅠ ( n = 25 ) to receive telmisartan 20 mg and indapamide 1.25 mg, the test group Ⅱ ( n = 25 ) to receive telmlsartan 20 mg and metoprolol tartrate 25 mg,bis in die;the controlled greup(n =24)to receive telmisartan 40 mg,once -daily. Results After 8 week of therapy,the total efficiency of the test group J, the test group D and the controlled group were 92. 0%, 83. 3 %, 62. 5 %, respeetively. Ⅰ and treatment set Ⅱ of the matched control, treatment set responds the occurrence number to distinguish to 4, 3 and 1 badly. The results showed that there were significant differences in the efficiency between the test group Ⅰ and the controlled group. Conclusion The results suggest that antihypertensive effects of the test group is more safe and better in treatment of hypertension.
出处 《中国医学创新》 CAS 2009年第10期23-25,共3页 Medical Innovation of China
关键词 高血压 替米沙坦 吲哒帕胺 酒石酸美托洛尔 Hypertension Telmisartan Indapamide Metoprelol tartrate
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部